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Qian Yang, Xiaoyong Qi* and Yingxiao LiAbstract
Background: A number of clinical and experimental studies have investigated the effect of atorvastatin on atrial
fibrillation (AF), but the results are equivocal. This meta-analysis was performed to evaluate whether atorvastatin can
reduce the risk of AF in different populations.
Methods: We searched PubMed, EMBASE and the Cochrane Database for all published studies that examined the
effect of atorvastatin therapy on AF up to April 2014. A random effects model was used when there was substantial
heterogeneity and a fixed effects model when there was negligible heterogeneity.
Results: Eighteen published studies including 9952 patients with sinus rhythm were identified for inclusion in the
analysis. Ten studies investigated primary prevention of AF by atorvastatin in patients without AF, seven studies
investigated secondary prevention of atorvastatin in patients with AF, and one study investigated mixed
populations of patients. Overall, atorvastatin was associated with a decreased risk of AF (odds ratio (OR) 0.51, 95%
confidence interval (CI) 0.36–0.70, P < 0.0001). However, subgroup analyses showed that in the primary prevention
subgroup (OR 0.55, 95% CI 0.38–0.81, P = 0.002), atorvastatin reduced the risk of new-onset AF in patients after
coronary surgery (OR 0.44, 95% CI 0.29–0.68, P = 0.0002), but had no beneficial effect in patients without coronary
surgery (OR 0.97, 95% CI 0.59–1.58, P = 0.89); in the secondary prevention subgroup, atorvastatin had no beneficial
effect on AF recurrence in patients with electrical cardioversion (EC) (OR 0.57, 95% CI 0.25–1.32, P = 0.19) or without
EC (OR 0.38, 95% CI 0.14–1.06, P = 0.06).
Conclusions: This meta-analysis suggests that atorvastatin has an overall protective effect against AF. However, this
preventive effect was not seen in all types of AF. Atorvastatin was significantly associated with a decreased risk of
new-onset AF in patients after coronary surgery. Moreover, atorvastatin did not prove to exert a significant protective
effect against the AF recurrences in both patients who had experienced sinus rhythm restoration by means of EC and
those who had obtained cardioversion by means of drug therapy. Thus, further prospective studies are warranted.
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Atrial fibrillation (AF) is the most common arrhythmia
in clinical practice and is a major contributor to morbidity
and mortality [1,2]. However, the mechanism of AF
remains incompletely understood and treatment is not
satisfactory. In recent years, an increasing number of
studies have suggested that inflammation and oxidative
stress contribute to atrial remodeling and play an important* Correspondence: hbghxiaoyong_q@126.com
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unless otherwise stated.role in AF development [2-4]. It has been suggested that
statin medications may be beneficial in protecting against
AF, because of their anti-inflammatory and antioxidant
properties [5]. Recent meta-analyses [6,7] of randomized
controlled trials (RCTs) showed that statin therapy was
significantly associated with a decreased risk of AF in
different patient populations. Atorvastatin is a highly
effective statin medication and is widely used clinically. It
is the most studied statin in relation to AF [6,7], but the
results are equivocal. We therefore performed thisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Summary of the study selection and exclusion
process. AF: atrial fibrillation.
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the risk of AF in different populations.
Methods
Literature search and inclusion criteria
We searched PubMed, EMBASE and the Cochrane
Database for all published studies that examined the effect
of atorvastatin therapy on AF up to April 2014. We
conducted text searches with the search terms “atorvastatin”
and “atrial fibrillation”. We also manually searched
references from selected clinical trials, recent meta-
analyses and review articles.
We included studies that met the following specified
criteria: (1) comparison of atorvastatin with placebo or
control treatment, regardless of the background therapy;
(2) randomized controlled human trials; (3) new-onset
AF or recurrent AF in each group as an outcome.
Data extraction and quality assessment
We extracted the following information from each study:
(1) study population sample size and characteristics; (2) dose
and duration of treatment; (3) outcome measures. One
reviewer abstracted the data, and then the other checked
the documentation. They finally reached an agreement on
the data by consensus. We used the Jadad score [8] to assess
the methodological quality of the included studies.
Statistical analysis
We performed the statistical calculations with RevMan
version 5.2 (The Cochrane Collaboration, Oxford, UK) and
Stata version 12 (Stata Corp, College Station, TX, USA).
We allocated the results of each study as dichotomous
frequency data to evaluate the effect of atorvastatin on
new-onset AF or recurrence of AF. We calculated the odds
ratio (OR) and 95% confidence interval (CI) for new-onset
or recurrent AF in each trial separately, and for combina-
tions of studies according to fixed-effect and random-effect
models. We used the chi-squared test to assess heterogen-
eity and I2 to quantify heterogeneity. If the chi-squared test
P-value was > 0.10 and I2 was < 50%, we analyzed the data
using a fixed-effect model (the Mantel–Haenszel method),
otherwise we used a random-effect model [9,10]. If
the heterogeneity was significant, we attempted to explain
the differences based on the patient clinical characteristics
of the included studies. The P-value threshold for statistical
significance was set at 0.05 for the effect sizes. We also
used Begg and Egger tests [11,12] to assess the presence of
publication bias.
Results
Characteristics of the included studies
Eighteen published studies [13-30] including 9952 patients
with sinus rhythm were identified for inclusion in the
analysis. The process of study selection is summarizedin Figure 1. These studies compared the use of atorvastatin
vs. no statins on AF in various populations. Ten studies
[15,17-19,21-24,26,28] investigated the use of atorvastatin
in primary prevention of AF in patients after cardiac
surgery (n = 8) [15,17,19,21-24,28] or implantation of a
pacemaker (n = 1) [18], or in patients with a prior stroke or
transient ischemic attack (n = 1) [26]. Seven studies
[14,16,20,25,27,29,30] investigated the use of atorvastatin
in secondary prevention of AF in patients who received
electrical cardioversion (EC; n = 4) [16,20,25,27], catheter
ablation (n = 2) [29,30] or pharmacological treatment
(n = 1) [14]. The MIRACL trial [13] included both AF
and non-AF patients, so MIRACL-1 and MIRACL-2
were used to represent the primary and secondary
prevention subgroups. These studies were published
between 2004 and 2013 and the sample sizes ranged from
40 to 4731. Intervention strategies of atorvastatin and
documentation of AF were also variable. The studies
received Jadad scores of 2 (n = 5) [16,18,21,27,30], 3
(n = 3) [14,19,24], 4 (n = 3) [15,23,29], or 5 (n = 7)
[13,17,20,22,25,26,28] points. The characteristics of
the studies included in the meta-analysis are shown
in Table 1.
Results of the meta-analysis
The meta-analysis of all included studies indicated
that atorvastatin was effective for the prevention of
AF (OR 0.51, 95% CI 0.36–0.70, P < 0.0001), but there
was substantial heterogeneity (P < 0.00001, I2 = 72%).
The results are shown in Figure 2.
Subgroup analysis
A subgroup analysis was performed to evaluate the
effect of atorvastatin on primary and secondary preven-
tion of AF. The results showed that atorvastatin was
effective for both primary prevention (OR 0.55, 95%
Table 1 Baseline characteristics of the studies included in the meta-analysis
Study, year n Population Dosage Duration Endpoint Documentation of AF Quality
score
MIRACL 2004 [13] 3087 Acute coronary syndrome 80 mg/d 16 weeks New onset or
recurrence of AF
Follow-up with ECG 5
Dernellis et al. 2005 [14] 80 Paroxysmal AF 20–40 mg/d 4–6 months Recurrence of AF 48-h ambulatory ECG
monitoring
3
Chello et al. 2006 [15] 40 Coronary bypass
surgery
20 mg/d 3 weeks New-onset AF after
cardiac surgery
ECG monitoring 4
Ozaydin et al. 2006 [16] 48 Persistent AF and
scheduled EC
10 mg/d 3 months Recurrence of AF 24-h ambulatory ECG
monitoring
2






Tsai et al. 2008 [18] 106 Bradyarrhythmia and
implantation of
pacemaker
20 mg/d 1 year AF/AHE≥ 10 min Pacemaker interrogation 2
Song et al. 2008 [19] 124 Off-pump coronary
bypass surgery






Almroth et al. 2009 [20] 234 Persistent AF and
scheduled EC
80 mg/d 30 days Recurrence of AF Follow-up with ECG 5
Melina et al. 2009 [21] 632 Coronary bypass
surgery
40 mg/d Not mentioned New-onset AF after
cardiac surgery
Not mentioned 2
Ji et al. 2009 [22] 140 Off-pump coronary
bypass surgery





Spadaccio et al. 2010 [23] 50 Coronary bypass
surgery
20 mg/d 7 days New-onset AF after
cardiac surgery
ECG monitoring 4
Sun et al. 2011 [24] 100 Coronary bypass
surgery
20 mg/d 14 days New-onset AF after
cardiac surgery
ECG monitoring 3
SToP AF 2011 [25] 64 Persistent AF and
scheduled EC




SPARCL 2011 [26] 4731 Prior stroke or
transient ischemic
attack
80 mg/d 4.8 years New-onset AF Follow-up with ECG 5
Demir et al. 2011 [27] 48 Persistent AF and
scheduled EC
40 mg/d 2 months Recurrence of AF Weekly follow-up
with ECG
2
Baran et al. 2012 [28] 60 Coronary bypass
surgery
40 mg/d 30 days New-onset AF after
cardiac surgery




Suleiman et al. 2012 [29] 125 AF undergoing
catheter ablation




Jiang et al. 2013 [30] 101 AF undergoing
catheter ablation
40 mg/d 6 months Recurrence of AF Not mentioned 2
AF: atrial fibrillation; AHE: Atrial high rate episode; ARMYDA-3: Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study; EC: Electrical
cardioversion; ECG: Electrocardiogram; MIRACL: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering study; SPARCL: Stroke Prevention by Aggressive
Reduction in Cholesterol Levels; SToP AF: statin therapy for the prevention of atrial fibrillation trial.
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(OR 0.47, 95% CI 0.26–0.86, P = 0.01) of AF. However, the
heterogeneity remained substantial (primary prevention:
P = 0.0004, I2 = 69%; secondary prevention: P = 0.002,
I2 = 70%) in both groups. The results are shown in Figure 3.
Eleven trials [15,17-19,21-24,26,28] that investigated the
use of atorvastatin in primary prevention of AF were
divided into two subgroups on the basis of whether patientsunderwent coronary surgery. The results of subgroup
analysis showed that atorvastatin was effective in reducing
the risk of AF in patients after coronary surgery (OR 0.44,
95% CI 0.29–0.68, P = 0.0002), although there was hetero-
geneity (P = 0.07, I2 = 46%), but showed no beneficial effect
in patients without coronary surgery (OR 0.97, 95% CI
0.59–1.58, P = 0.89), again showing heterogeneity (P = 0.12,
I2 = 53%). The results are presented in Figure 4.
Figure 2 Effect of atorvastatin on atrial fibrillation. ARMYDA-3: atorvastatin for reduction of myocardial dysrhythmia after cardiac surgery
study; CI: confidence interval; MIRACL: myocardial ischemia reduction with aggressive cholesterol lowering study; SPARCL: Stroke Prevention by
Aggressive Reduction in Cholesterol Levels; SToP AF: statin therapy for the prevention of atrial fibrillation trial.
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use of atorvastatin in secondary prevention of AF were
divided into two subgroups on the basis of whether
patients underwent EC. The results of subgroup analysis
showed that atorvastatin had no beneficial effect either in
patients with EC (OR 0.57, 95% CI 0.25–1.32, P = 0.19) or
without EC (OR 0.38, 95% CI 0.14–1.06, P = 0.06). The
heterogeneity remained substantial (with EC: P = 0.08,
I2 = 56%; without EC: P = 0.001, I2 = 81%) in both groups.
The results are shown in Figure 5.
Sensitivity analysis and publication bias
The results were similar when studies with Jadad
score < 3 [16,18,21,27,30] were removed from the analysis
(OR 0.49, 95% CI 0.32–0.73; P = 0.0004). These studies
were also excluded when performing the subgroup
analyses and no obvious change in effect size was
detected. However, there was little heterogeneity in
the coronary surgery subgroup (P = 0.96, I2 = 41%), so
a fixed-effect model was used to analyze the data.
The results are shown in Table 2.
Publication bias was evaluated using Begg’s and Egger’s
tests when the subgroup analyses were performed.Publication bias was statistically insignificant in patients
with EC (Begg, P = 1.00; Egger, P = 0.81), in patients with-
out EC (Begg, P = 0.73; Egger, P = 0.45), in patients without
coronary surgery (Begg, P = 0.30; Egger, P = 0.34), and
in patients with coronary surgery when a trial with
Jadad score < 3 was excluded [21] (Begg, P = 0.55;
Egger, P = 0.18).
Discussion
To the best of our knowledge, this is the first meta-
analysis that excluded bias caused by different types of
statins, and only assessed the efficacy of atorvastatin
on the prevention of AF in different populations. The
meta-analysis suggested that atorvastatin could protect
against AF overall. However, subgroup analysis indicated
that this preventive effect was not seen in all types of AF.
Atorvastatin was significantly associated with a decreased
risk of new-onset AF in patients after coronary surgery,
while atorvastatin did not prove to exert a significant pro-
tective effect against the AF recurrences in both patients
who had experienced sinus rhythm restoration by means
of EC and those who had obtained cardioversion by means
of drug therapy.
Figure 3 Primary and secondary prevention of AF with atorvastatin. AF: atrial fibrillation; ARMYDA-3: atorvastatin for reduction of myocardial
dysrhythmia after cardiac surgery study; CI: confidence interval; MIRACL: myocardial ischemia reduction with aggressive cholesterol lowering
study; SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels; SToP AF: statin therapy for the prevention of atrial fibrillation trial.
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more clinical studies related to AF have been carried out
with atorvastatin than with other statins. In the latest
meta-analysis [7], 28 RCTs were included to evaluate the
preventive effect of statin therapy on AF. Of the 28
trials, atorvastatin was studied in 16, indicating that
atorvastatin has the most evidenced-medicine data on
AF. The meta-analysis [7] included all types of statins and
suggested that statin therapy reduced AF significantly,
with an OR of 0.69 (95% CI 0.57–0.83). The presentmeta-analysis suggests that atorvastatin is a highly
effective statin medication in reducing AF, with an
overall OR of 0.51 (95% CI 0.36–0.70). Rosuvastatin
is another highly effective statin, but only limited data
are available about its potential effect on AF. A previous
meta-analysis of rosuvastatin [31] only included four RCTs
and showed that it reduced the risk of AF by 30% (relative
risk 0.70, 95% CI 0.54–0.91).
The preventive effect of atorvastatin against AF did
not appear to be dose-dependent, as the trials that used
Figure 4 Primary prevention of AF with atorvastatin in patients with or without coronary surgery. AF: atrial fibrillation; ARMYDA-3: atorvastatin
for reduction of myocardial dysrhythmia after cardiac surgery study; CI: confidence interval; MIRACL: myocardial ischemia reduction with aggressive
cholesterol lowering study; SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels.
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did not have lower ORs. Trials with different doses of
atorvastatin were limited and with significant heterogeneity
in the study populations, so subgroup analysis according to
different doses was not performed in our meta-analysis. A
previous meta-analysis [32] even came to the conclusion
that the preventive effect of atorvastatin on AF may be
more significant at a lower dose (10–40 mg/day), while a
recent study [33] on patients undergoing cardiac surgery
suggested that the preventive effect of atorvastatin on
postoperative AF was not dose-dependent.
In our meta-analysis, subgroup analyses were performed
to evaluate the effect of atorvastatin on AF in different
populations. Atorvastatin showed less atrial antiarrhythmic
properties than expected in different populations, espe-
cially in the prevention of AF recurrence. In the primary
prevention subgroup, the results showed that atorvastatin
was significantly associated with a decreased risk ofnew-onset AF in patients after coronary surgery (Figure 4),
which was in accord with other recent meta-analyses
[7,34]. However, atorvastatin did not appear to protect
against new-onset AF in patients who did not undergo
coronary surgery (Figure 4). However, as only three trials
were included in this subgroup and there was significant
heterogeneity among them, it is inappropriate to come to
the conclusion that atorvastatin was ineffective in this
population. A recent meta-analysis [7] included nine RCTs
and also found a negative result, which the authors
suggested may be attributed to a relatively short follow-up
time. In our secondary prevention subgroup, when trials
were divided into two groups of patients with or without
EC, the results showed that atorvastatin had no beneficial
effect on the recurrence of AF in either group (Figure 5).
These results contrasted with previous meta-analyses
[6,35], which suggested that statin therapy significantly
decreased the risk of AF recurrence in patients with or
Figure 5 Secondary prevention of AF with atorvastatin in patients with or without EC. AF: atrial fibrillation; CI: confidence interval; EC:
electrical cardioversion; MIRACL: myocardial ischemia reduction with aggressive cholesterol lowering study; SToP AF: statin therapy for the
prevention of atrial fibrillation trial.
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four trials were included in each subgroup and the
study population of each study was relatively small, it is
inappropriate to come to the conclusion that atorvastatin
is ineffective in the secondary prevention of AF, and
further investigation is required.
At present, an increasing amount of evidence suggests
that inflammation and oxidative stress may play importantTable 2 Sensitivity analysis
Number of trials
Variable Total After excluding 5
Overall 18 13
Primary prevention 11 9
With coronary surgery 8 7
Without coronary surgery 3 2
Secondary prevention 8 5
With electrical cardioversion 4 2
Without electrical cardioversion 4 3
CI: confidence interval; #Studies with Jadad score <3 were removed from the analysroles in the pathogenesis and perpetuation of AF [2,36,37].
The mechanism of action of statins in the treatment of AF
is suggested to be related to their anti-inflammatory and
antioxidant properties [4,38]. The capacity of statins to
reduce inflammation is relatively well established. Eight
trials [14-17,22,24,25,28] in our meta-analysis proved
that atorvastatin could reduce inflammatory biomarkers,
especially in patients after cardiac surgery [15,17,22,24,28]Effect size, odds ratio (95% CI)
trials# Total After excluding 5 trials#
0.51 (0.36 to 0.70) 0.49 (0.32 to 0.73)
0.55 (0.38 to 0.81) 0.51 (0.31 to 0.84)
0.44 (0.29 to 0.68) 0.36 (0.25 to 0.51)
0.97 (0.59 to 1.58) 1.14 (0.91 to 1.43)
0.47 (0.26 to 0.86) 0.46 (0.22 to 0.96)
0.57 (0.25 to 1.32) 0.63 (0.39 to 1.03)
0.38 (0.14 to 1.06) 0.38 (0.09 to 1.62)
is.
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the nicotinamide adenine dinucleotide phosphate oxidase
(NOX) is considered to be a very important cellular source
of reactive oxygen species (ROS) in the human body,
while excessive production of ROS is likely involved
in the structural and electrical remodeling of the heart, and
contributes to atrial fibrosis and AF [39]. Atorvastatin
could inhibit ROS generation via downregulation of
NOX2, thus protecting against AF [40]. In recent years,
myeloperoxidase (MPO), a heme enzyme abundantly
expressed by neutrophils, was shown to be a crucial
prerequisite for atrial fibrosis and AF [2,41]. Statins
could strongly inhibit MPO mRNA expression in human
and murine monocyte-macrophages, and consequently
reduce MPO protein and enzyme activity [42]. These may
be the underlying mechanisms of statin therapy on AF
and deserve further investigation.
This meta-analysis indicated that patients who underwent
coronary surgery derived more benefit from atorvastatin in
the prevention of AF than other populations. The reasons
can be summarized as follows. The postoperative course of
a coronary surgery is characterized by severe inflammation
and oxidative stress resulting from extracorporeal circula-
tion and surgical manipulation of the epicardial coronary
vessels. Thus the anti-inflammatory and antioxidant effects
of atorvastatin as mentioned above may account for its
beneficial effects in these patients. AF after coronary
surgery is mainly caused by elevations in atrial pressure,
autonomic nervous system imbalance, myocardial ischemic
damage and so on [43], thus it can regress over time with
surgery recovery. However, non-postoperative AF, especially
recurrent AF, is often caused by atrial remodeling
such as atrial dilation and fibrosis [44]. This remodeling
encompasses changes in electrical, contractile, and struc-
tural properties of the atria and may be less responsive to
atorvastatin compared with postoperative AF.
This meta-analysis has the following limitations. Only
published RCTs were included in our meta-analysis, so
publication bias was unavoidable. Although subgroup
analyses were performed according to different populations,
heterogeneity still existed among the trials, such as sample
size, the dose and duration of atorvastatin treatment, and
documentation of AF. The trials were limited according to
the numbers in some subgroups, so the results were less
persuasive.
Conclusions
The meta-analysis suggested that atorvastatin has an
overall protective effect against AF. However, subgroup
analysis indicated that this preventive effect was not seen
in all types of AF. Atorvastatin was significantly associated
with a decreased risk of new-onset AF in patients
after coronary surgery. Moreover, atorvastatin did not
prove to exert a significant protective effect againstthe AF recurrences in both patients who had experienced
sinus rhythm restoration by means of EC and those who
had obtained cardioversion by means of drug therapy.
Thus, more large-scale prospective RCTs are required to
investigate whether atorvastatin is an effective medication
for the prevention of AF in different populations.
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